# reload+after+2024-01-20 07:45:40.157526
address1§85 Wells Avenue
address2§2nd Floor
city§Newton
state§MA
zip§02459
country§United States
phone§617 658 0600
website§https://www.karyopharm.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
fullTimeEmployees§385
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Richard A. Paulson M.B.A.', 'age': 56, 'title': 'President, CEO & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 1364243, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sharon  Shacham M.B.A., Ph.D.', 'age': 53, 'title': 'Co-Founder & Chairman of Scientific Advisory Board', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1404313, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael P. Mason CPA, M.B.A.', 'age': 48, 'title': 'Executive VP, CFO & Treasurer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 681594, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael J. Mano J.D.', 'age': 46, 'title': 'Senior VP, General Counsel & Secretary', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 625075, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sohanya  Cheng M.B.A.', 'age': 40, 'title': 'Executive VP & Chief Commercial Officer', 'yearBorn': 1983, 'fiscalYear': 2022, 'totalPay': 664296, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stuart  Poulton', 'title': 'Executive VP & Chief Development Officer', 'fiscalYear': 2022, 'totalPay': 589792, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mansoor Raza Mirza M.D.', 'age': 62, 'title': 'Clinical Consultant, Member of Scientific Advisory Board & Independent Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 150000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Cameron  Peters', 'age': 63, 'title': 'Vice President of Finance, Assistant Treasurer & Principal Accounting Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elhan  Webb C.F.A.', 'title': 'Senior Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James  Accumanno J.D.', 'title': 'Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.214
priceToSalesTrailing12Months§0.64574856
currency§USD
dateShortInterest§1702598400
forwardEps§-0.91
pegRatio§0.02
exchange§NMS
quoteType§EQUITY
shortName§Karyopharm Therapeutics Inc.
longName§Karyopharm Therapeutics Inc.
firstTradeDateEpochUtc§1383748200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§5c4cd3b3-c1bf-3bcd-be28-a26f0ffcf89a
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§3.0
targetMeanPrice§6.0
targetMedianPrice§5.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§3.967
grossMargins§1.08938
ebitdaMargins§-0.79069
trailingPegRatio§None
